Behcet’s Disease Whole Blood

Behçet’s Disease Whole Blood for Variable-Vessel Vasculitis Research

Fresh Behçet’s Disease Whole Blood is collected from IRB-consented donors with clinically confirmed Behçet’s disease and shipped same day for maximum viability. Behçet’s disease is a chronic, relapsing, immune-mediated variable-vessel vasculitis whose classification is genuinely debated between autoinflammatory and autoimmune disease, and is best described as autoinflammatory-leaning. It features a strong HLA-B51 association, marked neutrophil hyperactivity, and Th1/Th17 skewing. Whole blood preserves every cellular compartment together with plasma, making it well suited to neutrophil function work, immunophenotyping, and genotyping from a single draw.

Behçet’s Immunobiology and Why Whole Blood

  • Variable-vessel vasculitis: inflammation can involve arteries and veins of any size, which sets Behçet’s apart from vasculitides defined by vessel calibre. Venous thrombosis, arterial involvement, and pulmonary artery aneurysm are recognized manifestations.
  • Immune-mediated and autoinflammatory-leaning: features span both categories — episodic sterile inflammation, innate cell hyperactivity, and IL-1 pathway involvement on the autoinflammatory side; a strong HLA association and adaptive T cell skewing on the autoimmune side. No defining autoantibody has been established for Behçet’s disease.
  • HLA-B51 and genetic risk: HLA-B*51 is the strongest known genetic association, with additional loci reported at IL10, IL23R-IL12RB2, and ERAP1. Whole blood yields high-quality genomic DNA for HLA typing and genotyping alongside cellular assays from the same specimen.
  • Neutrophil hyperactivity: increased chemotaxis, oxidative burst, and neutrophil extracellular trap formation are central to lesion pathology and to the pathergy phenomenon. These assays require fresh, unseparated blood with granulocytes intact.
  • Th1/Th17 skewing: elevated IFN-gamma, IL-17, IL-21, and TNF responses are consistent with the clinical utility of TNF inhibitors and, in certain manifestations, IL-1 or IL-17 pathway blockade.
  • Single-draw versatility: supports whole-blood stimulation assays, flow cytometry without density-gradient loss of granulocytes, RNA stabilization for transcriptomics, and DNA extraction from one collection.

Donor Stratification Available

  • Organ involvement: mucocutaneous (oral and genital ulcers), ocular (uveitis, retinal vasculitis), vascular (venous thrombosis, aneurysm), neuro-Behçet’s, gastrointestinal, or articular
  • HLA-B51 status where documented
  • Disease activity: active flare versus remission
  • Treatment status: colchicine, corticosteroid, azathioprine or other conventional immunosuppressant, TNF inhibitor, apremilast, or treatment-naive
  • Pathergy test result where documented
  • Geographic ancestry, including donors from populations along the historical Silk Road where prevalence is highest
  • Matched healthy controls available

Product Features

  • Research Use Only (RUO)
  • Fresh whole blood from clinically diagnosed Behçet’s disease donors
  • Custom tubes and anticoagulants available (EDTA, sodium citrate, sodium heparin, ACD)
  • Collected and shipped same-day for maximum freshness
  • IRB-approved protocols and electronic informed consent
  • Custom volumes available upon request

De-identified Donor Data

  • Confirmed Behçet’s disease diagnosis by physician or specialist
  • Demographic details: age, sex assigned at birth, race/ethnicity
  • Organ involvement pattern and disease activity status where documented
  • Medical history including current therapy, allergies, and infectious disease status

Applications

  • Neutrophil function assays: chemotaxis, oxidative burst, and NET formation
  • Whole-blood cytokine stimulation and immune activation profiling
  • Immunophenotyping of granulocyte, monocyte, T cell, and NK populations
  • HLA-B51 typing and genetic association studies
  • Gene expression and transcriptomic analysis in flare versus remission
  • IL-1, IL-17, and TNF pathway drug response and mechanism-of-action studies
  • Inflammatory marker and cytokine profiling
  • Biomarker discovery for disease activity and organ involvement

Other Behçet’s Disease Specimen Types

Compliance and Quality Assurance

  • IRB-approved protocols and electronic informed consent
  • HIPAA-compliant data management
  • Rigorous donor screening and documentation

Ordering & Customization

Behçet’s disease whole blood is available in a range of standard and custom volumes. For pricing, current availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse other conditions and live stock status, visit our human whole blood page.

Whole Blood

Frequently Asked Questions

Showing 1–12 of 26 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom Whole Blood cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information